Avinger (AVGR) Getting Somewhat Favorable Press Coverage, Study Finds

Several equities research analysts have recently weighed in on the company.

Avinger, Inc. (NASDAQ:AVGR) is scheduled to release its earnings data after the market closes on Monday, July 31st. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $6.00. Finally, Oppenheimer Holdings, Inc. reaffirmed a "market perform" rating on shares of Avinger in a research note on Wednesday, April 12th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The company's stock had a trading volume of 225,737 shares. Cowen and Company reissued a "buy" rating on shares of Avinger in a research report on Friday, April 14th. The stock's market capitalization is 11.00M, it has a 52-week low of 0.35 and a 52-week high of 5.15. The company now has a consensus rating of "Hold" and an average target price of $4.13.

COPYRIGHT VIOLATION NOTICE: "Avinger, Inc. (AVGR) Rating Lowered to Hold at Zacks Investment Research" was published by BNB Daily and is the property of of BNB Daily. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of USA & global trademark & copyright laws. Accern ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources.

A number of large investors have recently added to or reduced their stakes in the company. FMR LLC purchased a new position in shares of Avinger during the fourth quarter worth $5,772,000. IL now owns 73,900 shares of the medical device company's stock valued at $188,000 after buying an additional 3,500 shares during the period. Broadfin Capital LLC acquired a new stake in Avinger during the first quarter valued at about $950,000. IL increased its stake in Avinger by 5.0% in the first quarter.

Avinger, Inc is a commercial-stage medical device company. The Company designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral arterial disease (PAD).

Latest News